Renal Disease Clinical Trial
Official title:
Renal Oxygen Content is Increased in Healthy Subjects After Angiotensin Converting Enzyme Inhibition
It is well established that renal hypoxia is associated with the development of renal injury. The purpose of this study is measure the alterations in renal blood oxygenation after angiotensin II converting enzyme inhibition. The understanding of kidney adaptive mechanisms to renin angiotensin system effects in healthy subjects will be useful for the early detection of renal disease and for the development of new therapies to decrease the progression of the disease and its consequences.
Subjects The study will be conducted under a protocol (number 4111/08) approved by the
Ethics Committee of the Instituto de Cardiologia do Rio Grande do Sul-Fundação Universitária
de Cardiologia/Brazil. After giving their informed consent,the patients will participate in
the study. None of the subjects will take medication,food and water overnight. All
measurements will be performed at the end of the morning.
After control BOLD-MRI measurements acquisition, subjects will take an oral ACE inhibitor
(captopril 25 mg). Thirty minutes after captopril administration, without moving from the
scanner, blood pressure will be measured and a second BOLD acquisition will be performed to
detect a possible alteration in the renal oxygenation. Data will be collected by two
radiologists and interpreted by a physician and a physiologist.
MR Imaging Technique Images were acquired using 1.5T HDx (Sigma, GE Healthcare, Waukesha,
Win) and an 8 channels body coil.
Localizer images will be performed with axial and sagittal planes following the long axis of
both kidneys, using breath hold and fast spoiled gradient echo (FSPGR) technique.
Oblique axial and coronal reference images will be acquired for color maps following
approximately the short and long axis of both kidneys using FSPGR with the following
parameters: FOV=40cm, matrix 256x128, slice thickness=5cm, slice gap 6cm, 3 slices per plane
in one breath hold. TR=150ms, TE=min full, FLIP=90, rBW=62KHz, 1NEX. This sequence provides
an excellent contrast between cortex and medulla and avoid the unnecessary use of a contrast
agents.
BOLD sensitive images will be acquired using the multiple echo FGRE sequence with the same
geometrical parameters. The reference images considered will have the following parameters:
TR = 60ms, FLIP=30, rBW=60KHz, 16 echoes from TE=2.1ms until 49.6ms, echo interval of 3.2ms,
1 NEX.
BOLD imaging Data Processing Bold image processing will be performed using the Function R2*
module for R2*/T2* fitting, assuming single exponential decay without constant offset at
AW4.3 (GE Healthcare).
For visualization and quantification, R2* parametric maps will be generated for each
slice.(11, 18-19) A Puh Talium color table will be used, since it was a dynamic range with
minimum value set at 7.0/sec and maximum value at 23/sec. Color will be ranged from blue to
red, close to minimum R2* and below and close to maximum R2* and above, respectively. The
green/yellow will be assumed as intermediate. When a position mismatch due to a different
breath hold state, anatomical fat suppressed FSPGR images were used as transparent
references over a parametric map or original BOLD images.
One slice out of three, which provided the best differentiation between cortex and medulla
and minimum partial volume, will be selected for quantification. A total of 6 regions of
interest (ROI) with a 9 pixel size were used, 3 positioned at the cortex and 3 at the
medulla for each plane.
The ROIs will be positioned at the cortex according to the anatomical reference image (light
gray) and blue on the parametric map. The ROIs will be positioned at the medulla using
either the anatomical reference image (dark gray) or the parametric map that showed a green,
yellow and red gradient (figure 1). Areas with susceptibility artifacts, such as bowel gas
or areas with renal hilum vessels, will be avoided.
Data analysis The statistical analysis will be determined by variance test for three
repeated measures (ANOVA). Data are presented as the mean ± SD. P<0.05 will be considered
statistically significant.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
Completed |
NCT01545531 -
Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance
|
N/A | |
Recruiting |
NCT05700903 -
Contributions to Hypertension With Androgen Deprivation Therapy
|
Phase 4 | |
Completed |
NCT03717883 -
ADPKD Alterations in Hepatic Transporter Function
|
||
Withdrawn |
NCT04556721 -
A Pharmacokinetic Study of Sugammadex in Dialysis Patients
|
Phase 1 | |
Active, not recruiting |
NCT04078750 -
PLATO - Medication Adherence in Transplant Recipients
|
N/A | |
Not yet recruiting |
NCT04531124 -
Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives
|
||
Completed |
NCT03107195 -
Biokinetics Study of Tc-99m DMSA in Pediatric Molecular Imaging
|
||
Completed |
NCT03463148 -
Validation of a Sensor for Non-Invasive Measurements
|
||
Recruiting |
NCT03578523 -
Renal MR Feasibility in Renal Disease
|
||
Withdrawn |
NCT01468259 -
A Multi-Center, Open-Label Study
|
Phase 1 | |
Completed |
NCT01256983 -
Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
|
Phase 0 | |
Completed |
NCT06070337 -
H-Guard Pilot Safety Evaluation in Haemodialysis Patients
|
N/A | |
Completed |
NCT05593211 -
Assess Safety and Performance of the Kronos Electrocautery Device for Electrocautery Procedures Following Coaxial Biopsy Procedures
|
N/A | |
Completed |
NCT03242343 -
VasQ External Support for Arteriovenous Fistula
|
N/A | |
Completed |
NCT03438123 -
Data Collection Study for the Spectrum Dynamics Multi-purpose CZT SPECT Camera
|
N/A | |
Completed |
NCT01334333 -
Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT05443321 -
Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes
|
N/A | |
Completed |
NCT04407182 -
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT06419270 -
Cardiovascular, Renal, and Skeletal Complications in Patients With Post-Surgical Hypoparathyroidism
|